Pharmacovigilance for COVID-19 vaccines

  • Phase 1/2
    32Vaccines in

    Phase 1/2

  • Phase 3 - ongoing
    15Vaccines in

    Phase 2

  • Phase 3 - completed, but data not publicly available
    16Vaccines in

    Phase 2/3

  • Phase 3 - completed, but not formally published
    50Vaccines in

    Phase 3

  • Phase 3 - completed, published data
    11Vaccines in

    Phase 4

15 Emergency use listing (EUL) /WHO

50 Authorization issued by countries or regions

Disclaimer: It is important to note that the data on spontaneous reports of adverse events after vaccination are just suspicious adverse events. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Causal associations cannot (and should not) be made using data from spontaneous reports.
Moreover, this data is not valid for estimating the frequency of occurrence of adverse reactions in patients receiving the vaccine, nor do they allow comparisons between different vaccines. However, this data coming from spontaneous report can be useful to provide hypothesis, requiring additional epidemiological and clinical investigations to be confirmed or refuted. Further confirmation in controlled studies is usually required.

Loading vaccines...
  • Filter by:

    The vaccines detailed below have been prioritized based on their use in the Region of the Americas